With the SHI Financial Stabilisation Act (GKV-FinStG), the framework conditions for price negotiations for medicinal products in Germany have been made more complex and have been systematically tightened by the legislator to the disadvantage of the pharmaceutical industry. On the one hand the extend of the additional benefit and on the other hand the prices, patent protection, and previous benefit assessments of the comparative therapies have a major impact on negotiations of the reimbursement amount.
Try out our new guide, which will lead you through the various scenarios of the price negotiations following AMNOG benefit assessment. For further questions, we are happy to advise you!
After the implementation of the BStabG with far-reaching consequences, a reform of the AMNOG process itself (AMNOG 2.0) is now being discussed. Beyond that the Finance Committee on Health recently proposed expanding the role of cost-benefit assessments for reimbursement price negotiations, effective…
With the German Health Insurance Contribution Rate Stability Act (BStabG) now in force, statutory health insurances can establish cross-molecule rebate contracts for clusters of innovative, patent-protected medicines under §130e SGB For manufacturers, the implications are significant: Intensi…
The draft bill for the health care reform in Germany not only extends the price moratorium until 2030 but also cuts free pricing for nex Gx products. In the future, Gx prices for new products will depend on the existing market prices. The decisive factor will be whether a drug with the same active i…
The dynamic manufacturer rebate is a regulatory misstep The planned introduction of a dynamic manufacturer rebate for patent-protected medicines (§ 130a para. 1b SGB V) as part of the BStabG (statutory health insurance contribution rate stabilization bill) raises significant regulatory questions — p…
